| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.04 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.075 | 0.05 |
| mRNA | MP470 | GDSC1000 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | JQ12 | GDSC1000 | pan-cancer | AAC | -0.074 | 0.05 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.061 | 0.05 |
| mRNA | BRD-K28456706 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.05 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.066 | 0.05 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | 0.061 | 0.05 |